ArticleACS chemical neuroscience2019
Do Toxic Synthetic Cannabinoid Receptor Agonists Have Signature in Vitro Activity Profiles? A Case Study of AMB-FUBINACA.
Article in ACS chemical neuroscience, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 63 citations in OpenAlex.
- AB-MDMSBA-Not a Synthetic Cannabinoid Receptor Agonist.Pharmacology research & perspectives · 2026Article
- Article
- Article
- Insight into the mechanism of action of ORG27569 at the cannabinoid type one receptor utilising a unified mathematical model.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- Pharmacological evaluation of new generation OXIZID synthetic cannabinoid receptor agonists.European journal of pharmacology · 2024Article
- Evaluating signaling bias for synthetic cannabinoid receptor agonists at the cannabinoid CBPharmacology research & perspectives · 2023Article
- Cannabinoid 1 (CBBritish journal of pharmacology · 2023Article
- The piperazine analogue para-fluorophenylpiperazine alters timing of the physiological effects of the synthetic cannabinoid receptor agonist AMB-FUBINACA, without changing its discriminative stimulus, signalling effects, or metabolism.Pharmacology, biochemistry, and behavior · 2023Article
- Characterisation of AMB-FUBINACA metabolism and CBForensic toxicology · 2023Article
- In Vitro Characterization of 6-Methyl-3-(2-nitro-1-(thiophen-2-yl)ethyl)-2-phenyl-1ACS pharmacology & translational science · 2022Article
- Pharmacological affinity fingerprints derived from bioactivity data for the identification of designer drugs.Journal of cheminformatics · 2022Article
- Delineating the interactions between the cannabinoid CBBritish journal of pharmacology · 2022Article
- Structure-activity relationships of valine,RSC medicinal chemistry · 2022Article
- Exploring determinants of agonist efficacy at the CB1 cannabinoid receptor: Analogues of the synthetic cannabinoid receptor agonist EG-018.Pharmacology research & perspectives · 2022Article
- Off-target pharmacological profiling of synthetic cannabinoid receptor agonists including AMB-FUBINACA, CUMYL-PINACA, PB-22, and XLR-11.Frontiers in psychiatry · 2022Article
- The Spicy Story of Cannabimimetic Indoles.Molecules (Basel, Switzerland) · 2021Review
- Molecular signaling of synthetic cannabinoids: Comparison of CB1 receptor and TRPV1 channel activation.European journal of pharmacology · 2021Article
- A Systematic Study of the In Vitro Pharmacokinetics and Estimated Human In Vivo Clearance of Indole and Indazole-3-Carboxamide Synthetic Cannabinoid Receptor Agonists Detected on the Illicit Drug Market.Molecules (Basel, Switzerland) · 2021Article
- Overview of Synthetic Cannabinoids ADB-FUBINACA and AMB-FUBINACA: Clinical, Analytical, and Forensic Implications.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Molecular Pharmacology of Synthetic Cannabinoids: Delineating CB1 Receptor-Mediated Cell Signaling.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 3 countries.
Funding
Abstract
Recreational consumption of synthetic cannabinoid receptor agonists (SCRAs) is a growing crisis in public health in many parts of the world. AMB-FUBINACA is a member of this class of drugs and is responsible for a large proportion of SCRA-related toxicity both in New Zealand and internationally. Strikingly, little is currently known about the mechanisms by which SCRAs exert toxic effects or whether their activity through the CB
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.